Interleukin-17 Gene Expression and Serum Levels in AsthmaDegenerative Model

Area of Science:

• Immunology
• Respiratory Medicine
• Biochemistry

Background:

• Asthma is a prevalent chronic respiratory disease with increasing incidence.
• Interleukin-17 (IL-17) is implicated in the pathogenesis of severe asthma.
• Quantifying IL-17 in asthma can provide insights into disease severity.

Purpose of the Study:

• To quantitatively assess IL-17 gene expression in peripheral blood mononuclear cells (PBMN) and serum levels in asthmatic patients.
• To correlate IL-17 levels with asthma severity.
• To compare IL-17 gene expression with its serum concentration.

Main Methods:

• Real-time PCR was used to measure IL-17 mRNA gene expression in PBMN.
• Enzyme-linked immunosorbent assay (ELISA) quantified serum IL-17 levels.
• Asthma patients were categorized into controlled and uncontrolled groups based on GINA guidelines.

Main Results:

• Significantly higher serum IL-17 levels were observed in uncontrolled asthma patients (87.24 pg/ml) compared to controlled asthma (75.9 pg/ml) and healthy controls (47.0 pg/ml) (P=0.00).
• IL-17 mRNA gene expression levels were markedly elevated in uncontrolled asthma (33.7 units) versus controlled asthma (7.0 units) and healthy controls (0.30 units) (P=0.00).
• Both serum IL-17 and its gene expression showed a strong correlation with asthma severity.

Conclusions:

• Elevated IL-17 levels in both serum and PBMN are strongly associated with uncontrolled asthma.
• IL-17 serves as a potential biomarker for asthma severity.
• Targeting IL-17 pathways may offer therapeutic benefits for severe asthma.